Marina Fassarella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marina Fassarella has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Erwin Gerard Zoetendal
Laboratory of Microbiology, Wageningen University & Research, Wageningen, The Netherlands
2 shared publications - Cynthia E. Klostermann
Biobased Chemistry & Technology, https://dx.doi.org/4508Wageningen University & Research, Bornse Weilanden 9, 6708 WG Wageningen, The Netherlands
1 shared publication - Dorien Reijnders
Human Translational Physiology Pennington Biomedical Research Center Baton Rouge Louisiana USA
1 shared publication - Ellen E. Blaak
Department of Human Biology, NUTRIM Institute of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center
1 shared publication - Gijs H. Goossens
Department of Human Biology, Institute of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University Medical Centre+, Maastricht, The Netherlands
1 shared publication Hauke Smidt
Laboratory of Microbiology, Wageningen University & Research, Stippeneng 4, 6708 WE, Wageningen, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 27 June 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Translational human gut microbiome research: What are the missing pieces of the puzzle?
Human gut microbiome research has expanded remarkably over the past two decades, revealing the fundamental role of gut microbes in human health and disease. Despite these advances, translation into evidence-based clinical practice and public health implementation remains exceptionally limited. This integrative translational perspective review evaluates human gut microbiome research across four critical aspects: translational successes, barriers to effective translation, applicability of frameworks from other medical disciplines, and strategies to enhance translational progress. Human gut microbiome research was evaluated through the lens of translational medical research principles, as summarised below. (1) Translational successes in human gut microbiome research are explored by analysing the developmental pathways of major microbiome-based or microbiome-targeted approaches, including faecal microbiota transplantation, probiotics, postbiotics, prebiotics, and dietary interventions, despite overall limited clinical and public health translation. (2) Established translational medical research frameworks served as a foundation to identify missing elements in current human gut microbiome research, including progression through T0-T4 phases, bidirectional knowledge flow, prioritization of unmet patient and societal health needs, patient-centric approaches, stakeholder engagement, and interdisciplinary collaboration. Integration of these principles is discussed in light of the specific characteristics, challenges, and limitations of human gut microbiome research. (3) Translational barriers in human gut microbiome research were analysed beyond limited integration of translational medical principles. These arise from the inherent complexity and high-dimensional nature of the gut microbiome, temporal and inter-individual variability, confounding factors, inconsistent methodological standardization and validation, and fragmentation across research efforts. Collectively, these barriers hinder causal inference, resulting in a low-quality evidence base and limiting effective translation. (4) A framework to advance translational human gut microbiome research is proposed based on the previous findings, including strategic priorities such as education and training in translational research principles for gut microbiome researchers. Human gut microbiome research remains largely confined to early translational phases, with progression toward effective translation limited by intrinsic and methodological barriers that hinder causal inference and high-level evidence generation. Integration of core translational medical research principles offers a pathway to bridge these gaps, with education and training of gut microbiome researchers emerging as a key priority for advancing translational progress.
- 27 June 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessTranslational human gut microbiome research: What are the missing pieces of the puzzle?
Human gut microbiome research has expanded remarkably over the past two decades, revealing the fundamental role of gut microbes in human health and disease. Despite these advances, translation into evidence-based clinical practice and public health implementation remains exceptionally limited. This integrative translational perspective review evaluates human gut microbiome research across four critical aspects: translational successes, barriers to effective translation, applicability of frameworks from other medical disciplines, and strategies to enhance translational progress. Human gut microbiome research was evaluated through the lens of translational medical research principles, as summarised below. (1) Translational successes in human gut microbiome research are explored by analysing the developmental pathways of major microbiome-based or microbiome-targeted approaches, including faecal microbiota transplantation, probiotics, postbiotics, prebiotics, and dietary interventions, despite overall limited clinical and public health translation. (2) Established translational medical research frameworks served as a foundation to identify missing elements in current human gut microbiome research, including progression through T0-T4 phases, bidirectional knowledge flow, prioritization of unmet patient and societal health needs, patient-centric approaches, stakeholder engagement, and interdisciplinary collaboration. Integration of these principles is discussed in light of the specific characteristics, challenges, and limitations of human gut microbiome research. (3) Translational barriers in human gut microbiome research were analysed beyond limited integration of translational medical principles. These arise from the inherent complexity and high-dimensional nature of the gut microbiome, temporal and inter-individual variability, confounding factors, inconsistent methodological standardization and validation, and fragmentation across research efforts. Collectively, these barriers hinder causal inference, resulting in a low-quality evidence base and limiting effective translation. (4) A framework to advance translational human gut microbiome research is proposed based on the previous findings, including strategic priorities such as education and training in translational research principles for gut microbiome researchers. Human gut microbiome research remains largely confined to early translational phases, with progression toward effective translation limited by intrinsic and methodological barriers that hinder causal inference and high-level evidence generation. Integration of core translational medical research principles offers a pathway to bridge these gaps, with education and training of gut microbiome researchers emerging as a key priority for advancing translational progress.
- Open Access
- 29 April 2025
- Published by Walter de Gruyter GmbH in Beneficial Microbes
- Vol. 16 (6) , 687-706
Starch-degrading gut microbes Ruminococcus bromii and Bifidobacterium adolescentis differ in their ability to degrade resistant starch type 3
Intrinsic resistant starch type 3 (RS-3) is retrograded starch that is highly resistant to pancreatic digestion (≥80% RS) and will therefore transit to the colon largely intact. Two gut microbes, known as RS degraders, Ruminococcus bromii ATCC27255 and Bifidobacterium adolescentis L2-32, were studied for their ability to degrade intrinsic RS-3 with defined crystal type and chain length (A-type, degree of polymerisation (DP) 16 or DP 21; B-type, DP 32 or DP 76). Remaining glucose, malto-oligosaccharides and non-degraded insoluble RS-3 were quantified over time and remaining RS-3 was visualized by Scanning Electron Microscopy (SEM) over time and compared to degradation of granular maize and potato starch. R. bromii was not limited by any specific physico-chemical starch characteristic and degraded all substrates gradually to primarily maltose and glucose, although these sugars were not further utilised. In contrast, B. adolescentis was unable to degrade B-type intrinsic RS-3 and only slightly fermented A-type intrinsic RS-3 to acetate, whereas granular maize and potato starch were fermented readily to acetate and lactate. The extensive use of SEM in this study revealed the unique morphology of the RS-3 structures and the difference in degradation approach by the two gut microbes. It can be concluded that efficient degradation of intrinsic RS-3 requires microbes with specific enzyme machineries such as those present in R. bromii .
- 29 April 2025
- Published by Walter de Gruyter GmbH in Beneficial Microbes
- Vol. 16 (6) , 687-706
Open AccessStarch-degrading gut microbes Ruminococcus bromii and Bifidobacterium adolescentis differ in their ability to degrade resistant starch type 3
Intrinsic resistant starch type 3 (RS-3) is retrograded starch that is highly resistant to pancreatic digestion (≥80% RS) and will therefore transit to the colon largely intact. Two gut microbes, known as RS degraders, Ruminococcus bromii ATCC27255 and Bifidobacterium adolescentis L2-32, were studied for their ability to degrade intrinsic RS-3 with defined crystal type and chain length (A-type, degree of polymerisation (DP) 16 or DP 21; B-type, DP 32 or DP 76). Remaining glucose, malto-oligosaccharides and non-degraded insoluble RS-3 were quantified over time and remaining RS-3 was visualized by Scanning Electron Microscopy (SEM) over time and compared to degradation of granular maize and potato starch. R. bromii was not limited by any specific physico-chemical starch characteristic and degraded all substrates gradually to primarily maltose and glucose, although these sugars were not further utilised. In contrast, B. adolescentis was unable to degrade B-type intrinsic RS-3 and only slightly fermented A-type intrinsic RS-3 to acetate, whereas granular maize and potato starch were fermented readily to acetate and lactate. The extensive use of SEM in this study revealed the unique morphology of the RS-3 structures and the difference in degradation approach by the two gut microbes. It can be concluded that efficient degradation of intrinsic RS-3 requires microbes with specific enzyme machineries such as those present in R. bromii .
- Open Access
- 13 June 2022
- Published by Taylor & Francis in Gut Microbes
- Vol. 14 (1) , 2083905
Fecal carriage of vanB antibiotic resistance gene affects adipose tissue function under vancomycin use
Detrimental consequences of antibiotic treatment may include long-lasting disruption of the gut microbiota. Previous studies found no negative effects of antibiotics on metabolic health, although individualized responses were observed. Here, we aimed to investigate the subject-specific response to vancomycin use in tissue-specific insulin sensitivity by stratifying individuals based on the presence of antibiotic resistance genes (ARGs) or opportunistic pathogens (OPs) in the baseline fecal microbiota. Quantitative Polymerase Chain Reaction (qPCR) was used to detect ARGs and OPs in DNA isolated from fecal samples of 56 males with overweight/obesity (Body Mass Index: 25–35 kg/m2) and impaired glucose metabolism (fasting plasma glucose ≥5.6 mmol/L and/or 2-hour glucose 7.8–11.1 mmol/L). A two-step hyperinsulinemic-euglycemic clamp was performed to determine tissue-specific insulin sensitivity. Abdominal subcutaneous adipose tissue (AT) gene expression was assessed using Affymetrix microarray. Gut microbial composition was determined using the Human Intestinal Tract Chip (HITChip) microarray. At baseline, the vancomycin resistance gene vanB was present in 60% of our population. In individuals that were vanB-negative at baseline, AT insulin sensitivity (insulin-mediated suppression of plasma free fatty acids) improved during vancomycin use, while it decreased among vanB-positive individuals (% change post versus baseline: 14.1 ± 5.6 vs. −6.7 ± 7.5% (p = .042)). The vancomycin-induced increase in AT insulin sensitivity was accompanied by downregulation of inflammatory pathways and enrichment of extracellular matrix remodeling pathways in AT. In the vanB-positive group, well-known vanB-carrying bacteria, Enterococcus and Streptococcus, expanded in the gut microbiome. In conclusion, microbiome composition and adipose tissue biology were differentially affected by vancomycin treatment based on fecal vanB carriage.
- 13 June 2022
- Published by Taylor & Francis in Gut Microbes
- Vol. 14 (1) , 2083905
Open AccessFecal carriage of vanB antibiotic resistance gene affects adipose tissue function under vancomycin use
Detrimental consequences of antibiotic treatment may include long-lasting disruption of the gut microbiota. Previous studies found no negative effects of antibiotics on metabolic health, although individualized responses were observed. Here, we aimed to investigate the subject-specific response to vancomycin use in tissue-specific insulin sensitivity by stratifying individuals based on the presence of antibiotic resistance genes (ARGs) or opportunistic pathogens (OPs) in the baseline fecal microbiota. Quantitative Polymerase Chain Reaction (qPCR) was used to detect ARGs and OPs in DNA isolated from fecal samples of 56 males with overweight/obesity (Body Mass Index: 25–35 kg/m2) and impaired glucose metabolism (fasting plasma glucose ≥5.6 mmol/L and/or 2-hour glucose 7.8–11.1 mmol/L). A two-step hyperinsulinemic-euglycemic clamp was performed to determine tissue-specific insulin sensitivity. Abdominal subcutaneous adipose tissue (AT) gene expression was assessed using Affymetrix microarray. Gut microbial composition was determined using the Human Intestinal Tract Chip (HITChip) microarray. At baseline, the vancomycin resistance gene vanB was present in 60% of our population. In individuals that were vanB-negative at baseline, AT insulin sensitivity (insulin-mediated suppression of plasma free fatty acids) improved during vancomycin use, while it decreased among vanB-positive individuals (% change post versus baseline: 14.1 ± 5.6 vs. −6.7 ± 7.5% (p = .042)). The vancomycin-induced increase in AT insulin sensitivity was accompanied by downregulation of inflammatory pathways and enrichment of extracellular matrix remodeling pathways in AT. In the vanB-positive group, well-known vanB-carrying bacteria, Enterococcus and Streptococcus, expanded in the gut microbiome. In conclusion, microbiome composition and adipose tissue biology were differentially affected by vancomycin treatment based on fecal vanB carriage.